BVF group (NASDAQ: OLMA) reports 29,500 new options and large pre-funded warrants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Olema Pharmaceuticals director-affiliated investment entities reported updated holdings and a new equity award arrangement. Funds and entities associated with Biotechnology Value Fund and Mark N. Lampert jointly report common stock, stock options and pre-funded warrants and collectively disclaim beneficial ownership beyond their pecuniary interests.
A key update is a grant of 29,500 stock options with an exercise price of $9.51 per share, linked to director Gorjan Hrustanovic. These options vest in 12 equal monthly installments starting June 18, 2026, or sooner at Olema’s next annual stockholder meeting if not already fully vested, subject to his continued service.
The filing also lists substantial pre-funded warrants, each exercisable for one share of common stock at $0.0001 per share, subject to a 9.99% ownership cap to limit how many shares can be held immediately after any exercise.
Positive
- None.
Negative
- None.
Insider Trade Summary
16 transactions reported
Mixed
16 txns
Insider
BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N
Role
null | null | null | null | null | null | null | null | null | null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) | 29,500 | $0.00 | -- |
| holding | Pre-Funded Warrant | -- | -- | -- |
| holding | Pre-Funded Warrant | -- | -- | -- |
| holding | Pre-Funded Warrant | -- | -- | -- |
| holding | Stock Option (Right to buy) | -- | -- | -- |
| holding | Stock Option (Right to buy) | -- | -- | -- |
| holding | Stock Option (Right to buy) | -- | -- | -- |
| holding | Stock Option (Right to buy) | -- | -- | -- |
| holding | Stock Option (Right to buy) | -- | -- | -- |
| holding | Stock Option (Right to buy) | -- | -- | -- |
| holding | Stock Option (Right to buy) | -- | -- | -- |
| holding | Stock Option (Right to buy) | -- | -- | -- |
| holding | Common stock, $0.0001 par value | -- | -- | -- |
| holding | Common stock, $0.0001 par value | -- | -- | -- |
| holding | Common stock, $0.0001 par value | -- | -- | -- |
| holding | Common stock, $0.0001 par value | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to buy) — 29,500 shares (Indirect, See footnote);
Pre-Funded Warrant — 3,291,004 shares (Direct, null);
Common stock, $0.0001 par value — 2,655,977 shares (Direct, null);
Common stock, $0.0001 par value — 99,556 shares (Indirect, See footnote)
Footnotes (1)
- This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account. Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. The shares subject to the option have fully vested. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date.
Key Figures
New stock options granted: 29,500 options
Option exercise price: $9.51 per share
Pre-funded warrants block: 3,362,88 underlying shares
+5 more
8 metrics
New stock options granted
29,500 options
Grant to director-linked account on June 18, 2026
Option exercise price
$9.51 per share
Exercise price for 29,500-share stock option grant
Pre-funded warrants block
3,362,88 underlying shares
Pre-funded warrant position exercisable at $0.0001
Additional pre-funded warrants
2,627,590 underlying shares
Second pre-funded warrant position at $0.0001
Largest warrant position
3,291,004 underlying shares
Third pre-funded warrant block at $0.0001
Ownership cap
9.99%
Maximum common stock ownership allowed after warrant exercise
Director indirect common shares
99,556 shares
Indirect common stock holdings with footnote-described structure
Largest direct common block
3,291,004 shares
Direct common stock underlying a pre-funded warrant
Key Terms
Pre-Funded Warrant, Section 13(d) group, pecuniary interest, stock option, +2 more
6 terms
Pre-Funded Warrant financial
"Each Pre-Funded Warrant may be exercised for one share of Common Stock."
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
Section 13(d) group regulatory
"Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares."
pecuniary interest financial
"Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."
stock option financial
"The shares subject to the option vest in a series of 12 successive equal monthly installments."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
beneficial ownership regulatory
"may be deemed to beneficially own the securities owned directly by BVF."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
vesting financial
"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider activity did Olema Pharmaceuticals (OLMA) report in this Form 4?
Olema Pharmaceuticals reported a new stock option grant and updated holdings for entities tied to Biotechnology Value Fund and director Gorjan Hrustanovic. The filing is primarily administrative, detailing option terms, warrant positions, and beneficial ownership relationships rather than open-market share purchases or sales.
How many Olema (OLMA) stock options were granted and at what price?
The filing shows a grant of 29,500 stock options linked to director Gorjan Hrustanovic, with an exercise price of $9.51 per share. These options give the right to buy Olema common stock at that fixed price if and when they vest and are later exercised.
What are the vesting terms of the new Olema (OLMA) stock options?
The 29,500 options vest in 12 equal monthly installments starting June 18, 2026, contingent on Gorjan Hrustanovic’s continuous service. Any remaining unvested options vest in full at Olema’s next annual stockholder meeting if they are not already fully vested by that date.
What does the 9.99% ownership cap mean for Olema (OLMA) warrants?
The 9.99% ownership cap means a warrant holder cannot exercise pre-funded warrants if, before or after exercise, it would own more than 9.99% of Olema’s outstanding common shares. This constraint helps manage ownership concentration and possible regulatory or governance implications.
Who are the reporting persons in the Olema (OLMA) Form 4 and how do they relate?
Reporting persons include Biotechnology Value Fund entities, BVF Partners, BVF Inc., BVF GP entities and Mark N. Lampert, acting as a Section 13(d) group. They report shared economic exposure and relationships but each disclaims beneficial ownership beyond its direct pecuniary interest in Olema securities.